Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing ...

Investing.com -- Keros Therapeutics, Inc. (NASDAQ:KROS) shares rose 6% following the announcement of the effectiveness of its global license agreement with pharmaceutical giant Takeda. The deal ...

Keros Therapeutics said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a mid-stage study after reports of a safety issue, sending its shares ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer stability. Click for more on KROS.

April 10 (Reuters) - Keros Therapeutics (KROS.O), opens new tab has adopted a poison pill defense to fend off hostile takeovers, after some investors indicated a desire to influence the control of ...

Keros will cut 45% of its workforce, leaving 85 employees and saving about $17 million annually. No improvement in PVR or 6MWD was seen; higher pericardial effusions in cibotercept arms vs. placebo.

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth potential through 2029. Read why I rate KROS as a Hold.

Keros intends to provide a preliminary update regarding the status of the process within 60 days. The company also adopted a limited-duration stockholder rights plan, effective immediately.

Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth. "ADAR1 calls for Keros to restructure the business, ...

Keros has two other novel investigational candidates in its clinical-stage pipeline, elritercept (KER-050), ActRIIA fusion protein, and KER-065, a selective activin receptor ligand trap.